Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 06:51 am EDT
Share
Leap Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 13.39 million compared to USD 17.02 million a year ago. Basic loss per share from continuing operations was USD 0.91 compared to USD 1.5 a year ago. Diluted loss per share from continuing operations was USD 0.91 compared to USD 1.5 a year ago.
For the six months, net loss was USD 55.25 million compared to USD 27.4 million a year ago. Basic loss per share from continuing operations was USD 4.01 compared to USD 2.42 a year ago. Diluted loss per share from continuing operations was USD 4.01 compared to USD 2.42 a year ago.
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
LEAP THERAPEUTICS, INC. 
